SMARCA4

History

%%{init: { 'logLevel': 'debug', 'theme': 'dark' } }%% timeline title Publication timing 2012-11-11 : Richter : BL 2013-01-01 : Zhang : DLBCL 2017-01-26 : Krysiak : FL 2020-09-17 : Nadeu : MCL

Relevance tier by entity

Entity Tier Description
PMBL 1 high-confidence PMBL/cHL/GZL gene
BL 1-EE1 high-confidence BL generichterRecurrentMutationID32012a?
DLBCL 1-EE1 high-confidence DLBCL genelohrDiscoveryPrioritizationSomatic2012a?
FL 1 high-confidence FL genekrysiakRecurrentSomaticMutations2017b?
MCL 1 high-confidence MCL genenadeuGenomicEpigenomicInsights2020b?

Mutation incidence in large patient cohorts (GAMBL reanalysis)

Entity source frequency (%)
BL GAMBL genomes+capture 22.63
BL Thomas cohort 17.80
BL Panea cohort 18.80
DLBCL GAMBL genomes 3.25
DLBCL Schmitz cohort 2.98
DLBCL Reddy cohort 3.30
DLBCL Chapuy cohort 2.14
FL GAMBL genomes 4.16
MCL GAMBL genomes 4.74

Mutation pattern and selective pressure estimates

Entity aSHM Significant selection dN/dS (missense) dN/dS (nonsense)
BL No Yes 13.014 7.632
DLBCL No No 3.876 0.000
FL No No 11.081 0.000

View coding variants in ProteinPaint hg19 or hg38

View all variants in GenomePaint hg19 or hg38

SMARCA4 Expression

References

1.
Deng Q, Lakra P, Gou P, Yang H, Meydan C, Teater M, Chin C, Zhang W, Dinh T, Hussein U, Li X, Rojas E, Liu W, Reville PK, Kizhakeyil A, Barisic D, Parsons S, Wilson A, Henderson J, Scull B, Gurumurthy C, Vega F, Chadburn A, Cuglievan B, El-Mallawany NK, Allen C, Mason C, Melnick A, Green MR. SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. Cancer Cell. 2024 Apr 8;42(4):605–622.e11. PMCID: PMC11003852

Citing

If you use the information or data from this site, please cite

Krysta Coyle, Kostiantyn Dreval, Daniel Hodson and Ryan D. Morin. Audit of B-cell cancer genes. Blood Adv (2025) 9 (8): 2019–2031.

Disclaimer

The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

Share — copy and redistribute the material in any medium or format for any purpose, even commercially.

Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.